Coloplast A/S (CLPBY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Coloplast A/S (CLPBY) Healthcare & Pipeline Overview

Coloplast A/S, a Danish multinational, develops and markets specialized medical devices and services within ostomy, continence, wound, and skin care. With a strong global presence, the company distinguishes itself through innovative product design and a focus on improving the quality of life for people with intimate healthcare needs, competing in the medical instruments and supplies sector.

What Is the Investment Thesis for CLPBY?

With a market capitalization of $14.8B and a P/E ratio of 34.82, the company demonstrates financial stability. A gross margin of 65.0% and a profit margin of 14.3% indicate efficient operations and strong pricing power. Key value drivers include continued innovation in product development, expansion into emerging markets, and strategic acquisitions. Upcoming catalysts include new product launches in the wound care segment and potential regulatory approvals for urological devices. Potential risks include increasing competition from generic manufacturers and fluctuations in currency exchange rates.

Based on FMP financials and quantitative analysis

CLPBY Key Highlights

Market capitalization of $14.8B reflects Coloplast's significant presence in the medical instruments and supplies market.

• P/E ratio of 34.82 indicates investor confidence in Coloplast's earnings potential compared to the industry average.
• Gross margin of 65.0% demonstrates Coloplast's ability to maintain profitability through efficient production and pricing strategies.
• Profit margin of 14.3% highlights Coloplast's effective cost management and operational efficiency.
• Dividend yield of 5.14% offers investors a steady income stream, reflecting the company's commitment to shareholder returns.

Who Are CLPBY's Competitors?

CLPBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CLPBY's Key Strengths?

Strong brand recognition and customer loyalty.

• Diversified product portfolio across multiple healthcare segments.
• Global presence and established distribution network.
• Consistent profitability and strong financial performance.

What Are CLPBY's Weaknesses?

Exposure to currency exchange rate fluctuations.

• Dependence on regulatory approvals for new products.
• Potential for product recalls or liability claims.
• Limited presence in some emerging markets.

What Could Drive CLPBY Stock Higher?

Launch of new ostomy care products with enhanced features in Q3 2026.

• Expansion of digital health solutions to improve patient engagement and adherence.
• Strategic partnerships with healthcare providers to expand market reach.
• Regulatory approvals for innovative wound care technologies by end of 2026.

What Are the Key Risks for CLPBY?

Rich valuation — a P/E of 34.82 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Increasing competition from generic manufacturers in key product segments.
• Fluctuations in currency exchange rates impacting revenue and profitability.
• Regulatory changes and pricing pressures affecting reimbursement rates.
• Product recalls or liability claims related to product safety or efficacy.
• Economic downturns affecting healthcare spending and demand for elective procedures.

What Are the Growth Opportunities for CLPBY?

• Expansion in Emerging Markets: Coloplast has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing awareness of advanced medical technologies. By tailoring its product offerings to meet the specific needs of these markets and establishing strategic partnerships with local distributors, Coloplast can tap into a large and growing customer base. This expansion could contribute to a 10-15% increase in revenue over the next three to five years.
• New Product Development in Wound Care: Coloplast can drive growth through continued innovation in its wound care segment. The global wound care market is projected to reach $22 billion by 2028, driven by the increasing prevalence of chronic wounds and advancements in wound healing technologies. By developing advanced wound dressings and therapies that address unmet clinical needs, Coloplast can capture a larger share of this market. Focus should be on products that reduce healing time and improve patient outcomes.
• Strategic Acquisitions: Coloplast can pursue strategic acquisitions to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or established market positions in key regions, Coloplast can accelerate its growth and enhance its competitive advantage. Potential acquisition targets include companies specializing in advanced wound care, urological devices, or ostomy care products. These acquisitions can provide access to new markets and technologies, driving long-term growth.
• Digital Health Solutions: Coloplast can leverage digital health technologies to enhance its product offerings and improve patient outcomes. By developing mobile apps and online platforms that provide patients with personalized support and education, Coloplast can improve adherence to treatment plans and enhance patient satisfaction. These digital solutions can also generate valuable data that can be used to improve product development and marketing strategies. The market for digital health solutions is expected to grow significantly in the coming years, presenting a major opportunity for Coloplast.
• Focus on Personalized Healthcare: Coloplast can capitalize on the growing trend towards personalized healthcare by developing products and services that are tailored to the individual needs of patients. This includes using data analytics and artificial intelligence to identify patients who are most likely to benefit from specific treatments and developing customized product solutions. By focusing on personalized healthcare, Coloplast can improve patient outcomes, enhance customer loyalty, and differentiate itself from competitors. This approach aligns with the broader industry trend towards precision medicine and patient-centric care.

What Are CLPBY's Competitive Advantages?

• Strong brand reputation and customer loyalty in specialized healthcare segments.
• Extensive product portfolio and innovative product development capabilities.
• Global distribution network and established relationships with healthcare providers.
• Proprietary technologies and patents protecting key products.
• High barriers to entry due to regulatory requirements and specialized knowledge.

What Does CLPBY Do?

Founded in 1954 in Denmark, Coloplast A/S has evolved into a global leader in intimate healthcare solutions. The company's origins trace back to a nurse's invention of the world's first self-adhesive ostomy bag, a breakthrough that laid the foundation for Coloplast's commitment to innovation and patient-centric care. Today, Coloplast operates in three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Its product portfolio includes ostomy care products like SenSura Mio and Brava accessories, continence care solutions such as Conveen Active urine bags and SpeediCath catheters, and wound care products like Biatain Silicone and Comfeel dressings. Additionally, Coloplast offers skin care products and solutions for surgical treatment of urological and gynecological disorders. With a presence in over 40 countries, Coloplast serves a diverse range of healthcare professionals, patients, and caregivers, focusing on improving the quality of life for individuals with intimate healthcare needs. Headquartered in Humlebæk, Denmark, Coloplast continues to invest in research and development to maintain its competitive edge and expand its product offerings.

What Products and Services Does CLPBY Offer?

• Develop and market ostomy care products, including bags and accessories.
• Provide continence care solutions such as catheters and urine bags.
• Offer wound care products, including dressings and skin protectants.
• Develop and market products for surgical treatment of urological and gynecological disorders.
• Provide skin care products including cleansers, moisturizers, and protectants.
• Offer digital solutions to support patients in managing their conditions.

How Does CLPBY Make Money?

• Develops and manufactures medical devices and related products.
• Markets and sells products directly to healthcare providers and patients.
• Distributes products through a network of distributors and retailers.
• Generates revenue through product sales and related services.

What Industry Does CLPBY Operate In?

Coloplast A/S operates within the global medical instruments and supplies industry, a sector characterized by increasing demand driven by an aging population and rising prevalence of chronic diseases. The market is competitive, with key players focusing on innovation, product differentiation, and geographic expansion. The industry is also subject to stringent regulatory requirements and pricing pressures. Coloplast's focus on specialized segments like ostomy care and continence care allows it to maintain a competitive edge through differentiated products and strong brand recognition. The global medical devices market is projected to reach $600 billion by 2026, presenting significant growth opportunities for companies like Coloplast.

Who Are CLPBY's Key Customers?

• Hospitals and clinics
• Healthcare professionals (doctors, nurses, etc.)
• Patients with ostomies, incontinence, or wounds
• Retail pharmacies and medical supply stores

Company Profile

Coloplast A/S operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Humlebæk, DK. The company is led by CEO Gavin Wood. CLPBY has traded publicly since 2014.

Coloplast A/S Financial Trajectory

Coloplast A/S (CLPBY) reported $1.16B in revenue for Q3 FY2026, reflecting 3.9% growth compared to the prior quarter. The company recorded net income of $230.9M, with diluted EPS of $0.10. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, CLPBY averaged $0.05 in diluted EPS.

How Coloplast A/S Is Valued

Coloplast A/S carries a market capitalization of $14.8B, placing it in the large-cap category. Relative to its peer group, CLPBY's quantitative score of 48/100 is roughly in line with the peer average of 51/100.

Return on equity for Coloplast A/S stands at 14.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.5%, showing how much profit it generates from its asset base. CLPBY trades at a trailing price-to-earnings ratio of 34.82, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.

Coloplast A/S's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.38 places it in the safe zone, indicating low near-term bankruptcy risk.

Coloplast A/S has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 68.2% above estimates on average.

CLPBY Financials

CLPBY Latest News

CLPBY Analyst Consensus

CLPBY MoonshotScore

CLPBY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources